These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 7121729)
1. [Pathological changes of prolactinomas treated with bromocriptine]. Teramoto A; Takakura K; Fukushima T; Osamura Y No Shinkei Geka; 1982 Jun; 10(6):619-27. PubMed ID: 7121729 [TBL] [Abstract][Full Text] [Related]
2. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702 [TBL] [Abstract][Full Text] [Related]
3. [Size reduction of a nonfunctioning pituitary adenoma after bromocriptine therapy: case report]. Takahashi T; Kuwayama A; Katoh T; Ichihara K; Kageyama N; Sasaki F No Shinkei Geka; 1984 Jan; 12(1):71-80. PubMed ID: 6717737 [TBL] [Abstract][Full Text] [Related]
4. Cytosuppressive effect of bromocriptine on human prolactinomas: stereological analysis of ultrastructural alterations with special reference to secretory granules. Saitoh Y; Mori S; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H Cancer Res; 1986 Mar; 46(3):1507-12. PubMed ID: 3943108 [TBL] [Abstract][Full Text] [Related]
5. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma. Eljarmak D; Lis M; Cantin M; Carrière PD; Collu R Horm Res; 1985; 21(3):160-7. PubMed ID: 3997065 [TBL] [Abstract][Full Text] [Related]
6. [Medical treatment of prolactin-secreting pituitary adenomas. Influence of the size of the adenoma]. Kuhn JM; Gancel A; Weinstein A; Courtois H; Schrub JC; Tadie M; Wolf LM Presse Med; 1985 Mar; 14(9):525-8. PubMed ID: 3157164 [TBL] [Abstract][Full Text] [Related]
7. Prolactin-secreting adenomas: the preoperative response to bromocriptine treatment and surgical outcome. Hubbard JL; Scheithauer BW; Abboud CF; Laws ER J Neurosurg; 1987 Dec; 67(6):816-21. PubMed ID: 3681421 [TBL] [Abstract][Full Text] [Related]
8. Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? Landolt AM; Osterwalder V J Clin Endocrinol Metab; 1984 Jun; 58(6):1179-83. PubMed ID: 6725514 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment. Niwa J; Minase T; Hashi K; Mori M Virchows Arch B Cell Pathol Incl Mol Pathol; 1987; 53(2):89-96. PubMed ID: 2887062 [TBL] [Abstract][Full Text] [Related]
10. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas. Jones TH; Figueroa CD; Smith CM; Bhoola KD Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825 [TBL] [Abstract][Full Text] [Related]
11. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. Esiri MM; Bevan JS; Burke CW; Adams CB J Clin Endocrinol Metab; 1986 Aug; 63(2):383-8. PubMed ID: 3722328 [TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: ultrastructural alterations of secretory granules. Saitoh Y; Koizumi K; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H Anticancer Res; 1986; 6(5):1149-55. PubMed ID: 3800323 [TBL] [Abstract][Full Text] [Related]
13. Necrotic changes in prolactinomas after long term administration of bromocriptine. Gen M; Uozumi T; Ohta M; Ito A; Kajiwara H; Mori S J Clin Endocrinol Metab; 1984 Sep; 59(3):463-70. PubMed ID: 6746860 [TBL] [Abstract][Full Text] [Related]
14. Effect of vasoactive intestinal polypeptide (VIP) on growth hormone (GH) and prolactin (PRL) release and cell morphology in human pituitary adenoma cell cultures. Fazekas I; Bácsy E; Varga I; Slowik F; Bálint K; Pásztor E; Czirják S; Gláz E Folia Histochem Cytobiol; 2000; 38(3):119-27. PubMed ID: 10970071 [TBL] [Abstract][Full Text] [Related]
15. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. Bassetti M; Spada A; Pezzo G; Giannattasio G J Clin Endocrinol Metab; 1984 Feb; 58(2):268-73. PubMed ID: 6693536 [TBL] [Abstract][Full Text] [Related]
16. Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine. Osamura RY; Watanabe K Acta Pathol Jpn; 1986 Aug; 36(8):1131-7. PubMed ID: 3776530 [TBL] [Abstract][Full Text] [Related]
17. Necroses of prolactin-secreting pituitary adenomas under treatment with dopamine agonists: light microscopical and morphometric studies. Hallenga B; Saeger W; Lüdecke DK Exp Clin Endocrinol; 1988 Sep; 92(1):59-68. PubMed ID: 2906615 [TBL] [Abstract][Full Text] [Related]
18. Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology. Nissim M; Ambrosi B; Bernasconi V; Giannattasio G; Giovanelli MA; Bassetti M; Vaccari U; Moriondo P; Spada A; Travaglini P; Faglia G J Endocrinol Invest; 1982; 5(6):409-15. PubMed ID: 7169515 [No Abstract] [Full Text] [Related]
19. [Bromocriptine treatment of prolactinomas and primary hyperprolactinemia (author's transl)]. Fossati P; Grenier JL; Stevenard C; Fermon C; Christiaens JL; Linquette M Ann Med Interne (Paris); 1982; 133(1):45-7. PubMed ID: 7065588 [TBL] [Abstract][Full Text] [Related]
20. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. Tindall GT; Kovacs K; Horvath E; Thorner MO J Clin Endocrinol Metab; 1982 Dec; 55(6):1178-83. PubMed ID: 6752167 [No Abstract] [Full Text] [Related] [Next] [New Search]